Interview: George Yeh, President, Taiwan Liposome Company (TLC), Taiwan
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to…
Taiwan Liposome Company
Last updated: 13.02.2014
Taiwan Liposome Company
Taiwan Liposome Company (TLC) is a specialty biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products based on its proprietary drug delivery technologies for improving the treatment of cancers, peripheral arterial disease (PAD), ophthalmology and infectious diseases. Our strengths lie in utilizing lipid-based formulation for the optimization of pharmacokinetics for better efficacy and lower toxicity. TLC has developed five proprietary technology platforms which are used in nine products, including one marketed product, two products with drug approval and one NCE product in Phase II.
Since its inception in 1997, TLC has received several important awards and government grants. It was chosen among Red Herring Asia top 100 private companies in 2006, and shortlisted for Red Herring Global 100 in 2007. TLC was publicly listed in Taiwan on 21st December, 2012, and was selected into MSCI Global Small Cap Indices as of 31 May, 2013.
Interviews
Related
Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s…
Johnsee Lee – Chairman & CEO & Eric Yang – VP, Quark…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their…
Louis Cheng – CEO, Leadgene Biomedical, Taiwan
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody…
Johnsee Lee – Chairman, Taiwan Bio Industry Organization; President &…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s…
First Impressions / Taiwanese Pharma
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that…
Report / New Taiwan Pharma Report November 2019 Out Now
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an…
APAC / Taiwanese Pharma Looking Locally for International Opportunities
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market,…
Talent / Multinationals' HR Strategies in Taiwan
All country managers of multinational pharma companies need to strike the balance between having a global outlook…
Stanley Huang – Founder & Managing Director, Nutrarex Biotech, Taiwan
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively…
APAC / Taiwan's New Southbound Policy: Enhancing Regional Ties
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland…
Company Profile / iXensor, Taiwan
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which…
Mark Yang – CEO, GaleMed, Taiwan
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned…
